Researchers assessed the Intracept treatment in a Level 1, randomized and sham-controlled trial inclusive of 225 patients with chronic low back pain. Of the patients, 147 received the Intracept procedure and 78 underwent a sham procedure at 15 U.S. and three European Union sites.
The European Spine Journal published the trial’s results.
Here are four takeaways:
1. The study revealed the protocol Intracept treatment group saw a mean Oswestry Disability Index of 20.5 points at three months. This reflects a 48 percent decline from baseline.
2. The Intracept patients also experienced statistically significant drops in pain on the Visual Analog Scale, with a 44 percent decrease in pain at six months and 41 percent drop at 12 months.
3. Researchers saw no device-related adverse events.
4. A minimally invasive procedure, the Intracept targets the basivertebral nerve via a transpedicular approach and ablates the nerve with radiofrequency energy.
More articles on devices:
NuVasive names BD exec to board: 5 things to know
Robots, R&D top focus for Smith & Nephew’s knee business in 2018: 6 key quotes from CEO Oliver Bohoun
Stryker, Medicrea & more: 4 device company mergers, acquisitions and agreements
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
